ViroPharma Makes Smart Bet On Split Indications For HAE With Lev Deal

ViroPharma's proposed acquisition of Lev Pharmaceuticals covers contingencies for the various regulatory outcomes for Lev's crown jewel, the hereditary angioedema therapy Cinryze, including a possible escape hatch